Sumary of FDA approves oral ALS treatment:
- The FDA has approved Radicava ORS oral suspension for the care of adults with ALS.
- The most common side effects include bruising, gait disturbances, headaches and fatigue.
- Radicava (edaravone, Mitsubishi Tanabe Pharma) was originally approved in 2017 as a care for ALS via IV solution, the FDA said in a press release.
- An examination show that the daily functioning of those act Radicava ORS declined less on clinical classification analyze with those who collect medicine, the FDA stated.